Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction:Analysis from the CVD-REAL 2 study
- Lam, Carolyn S. P.
- Karasik, Avraham
- Melzer-Cohen, Cheli
- Cavender, Matthew A.
- Kohsaka, Shun
- Norhammar, Anna
- Thuresson, Marcus
- Chen, Hungta
- Wittbrodt, Eric
- Fenici, Peter
- Kosiborod, Mikhail
DOIAbstract
This study of real-world data from the Maccabi database in Israel compared the risk of heart failure hospitalization (HHF) or death in patients with type 2 diabetes (T2D) initiating sodium-glucose cotransporter-2 (SGLT2) inhibitors versus other glucose-lowering drugs (OGLDs) according to baseline left ventricular (LV) ejection fraction (EF). After propensity-matching patients by baseline EF there were 10 614 episodes of treatment initiation; 57% had diabetes for >10 years, the mean glycated haemoglobin level was 66 mmol/mol (8.2%), similar to 43% had cardiovascular disease, similar to 7% had heart failure and similar to 20% had chronic kidney disease. A total of 2876 patients (similar to 9%) had reduced EF (</p
Add to ORKG